Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; CAPRI-GOIM investigators. Normanno N, et al. Among authors: troiani t. Ann Oncol. 2015 Aug;26(8):1710-4. doi: 10.1093/annonc/mdv176. Epub 2015 Apr 7. Ann Oncol. 2015. PMID: 25851630 Free article. Clinical Trial.
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G. Ciardiello F, et al. Among authors: troiani t. Clin Cancer Res. 2004 Jan 15;10(2):784-93. doi: 10.1158/1078-0432.ccr-1100-03. Clin Cancer Res. 2004. PMID: 14760102
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F. Tuccillo C, et al. Among authors: troiani t. Clin Cancer Res. 2005 Feb 1;11(3):1268-76. Clin Cancer Res. 2005. PMID: 15709198
Antiangiogenic drugs in non-small cell lung cancer treatment.
Cascone T, Troiani T, Morelli MP, Gridelli C, Ciardiello F. Cascone T, et al. Among authors: troiani t. Curr Opin Oncol. 2006 Mar;18(2):151-5. doi: 10.1097/01.cco.0000208788.99570.0e. Curr Opin Oncol. 2006. PMID: 16462184 Review.
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR. Ciardiello F, et al. Among authors: troiani t. Br J Cancer. 2006 Jun 5;94(11):1604-9. doi: 10.1038/sj.bjc.6603141. Br J Cancer. 2006. PMID: 16685276 Free PMC article. Clinical Trial.
205 results